FREE Daily Stock Alerts From Stock-PR.com
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, today announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.
In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3’s depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. Power3 intends to appeal this decision.
“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”
Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
Parkinson’s disease (PD) is part of a team of ailments known as motor system disorders, which are the result of the loss of dopamine-producing brain cells. The 4 fundamental symptoms of PD are tremor, or moving in hands, arms, legs, jaw, and face; hardness, or perhaps tightness of your limbs and trunk; bradykinesia, or slowness to move; and postural lack of stability, or inable sense of balance and also co-ordination. As far as signs and symptoms, they are more noticable, patients might have trouble walking, talking, or finishing many other very simple tasks.
International, breast cancer consists of 10.4% in all cancer incidence among the ladies, defining it as the most common method of non-skin cancer in females and then the 5th most typical reason for cancer death. In 04, cancer of the breast induced 519,000 fatalities globally (7% connected with cancer deaths; practically 1% of all deaths). Breast cancers is about one hundred times more widespread in women than in men, even though men generally have poorer success on account of delays in medical diagnosis.
Alzheimer’s has no current cure, nonetheless treatments designed for conditions can be purchased and research continues on. Even though most current Alzheimer treatments can’t eliminate Alzheimer’s disease from progressing, they’re able to temporarily impede the worsening connected with symptoms as well as advance well being for anyone with Alzheimer’s not to mention all their caregivers. Today, there exists a world-wide exertion under way to find better ways to take care of the disease, delay its onset, and forestall it from evolving.
Mattel Inc (Nasdaq:MAT) the world’s largest toy company, jointly announced with the Mattel Children’s Foundation a multi-year disaster response strategy, which includes a $750,000 cash donation and toy donation program in partnership with Save the Children and the American Red Cross. The initiative represents a strategic focus and groundbreaking shift toward corporate support of proactive preparedness planning with first responder organizations for immediate disaster relief globally when needs arise.
Mattel, Inc., together with its subsidiaries, engages in the design, manufacture, and marketing of various toy products worldwide.
Masimo Corporation (Nasdaq:MASI) announced that it will release fourth quarter and full year 2010 financial results for the period ended January 1, 2011, after the market closes on February 15, 2011. A conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive patient monitoring products worldwide.
Blackbaud Inc. (Nasdaq:BLKB) announced that it has hired Richard Becker as president of Target Analytics, a Blackbaud company offering solutions for donor acquisition, prospect research, benchmarking, custom modeling, and data enrichment to more than 6,000 nonprofits. Target Analytics is the only company that provides a comprehensive solution which helps nonprofits replenish their donor pool, identify best prospects, provide peer-to-peer comparisons, and ensure a nonprofit’s information is as accurate as possible.
Blackbaud, Inc. provides software and related services for nonprofit organizations worldwide. Its solutions include The Raiser’s Edge, a software application to manage nonprofit organizations’ constituent relationship management activity.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.